Compound rupatadine bioadhesion nasal gel product and preparation method

Abstract

The invention discloses a compound rupatadine bioadhesion nasal gel product and a preparation method. The compound rupatadine bioadhesion nasal gel product is characterized by being prepared from, 10-100 parts of rupatadine and salts thereof, 5-20 parts of xylometazoline hydrochloride / naphazoline / pseudoephedrine hydrochloride, 1-4 parts of furacilin, 300-5000 parts of polymer gel materials, 2-200 parts of a biological adhesive, 180-200 parts of a buffer salt, 800-1600 parts of a wetting agent and 20000 parts of sterile water for injection. The wetting agent is dissolved into 2 / 3 of the sterile water for injection to obtain a solution A; the polymer gel material is stirred and added into the solution A to obtain a gel system B; the biological adhesive is dispersed into the gel system B to obtain a gel system C; the rupatadine and salts thereof, the xylometazoline hydrochloride / naphazoline / pseudoephedrine hydrochloride, the furacilin and the buffer salt are successively added into 1 / 3 of the sterile water for injection, and sonication is performed to obtain a solution D; the solution D is dispersed into the gel system C, and stirring is performed to obtain the final product.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a bioadhesive gel preparation for treating allergic and acute rhinitis containing rupatadine and its salt, a vasoconstrictor and an anti-infective drug nitrofurazone. Background technique [0002] Allergic rhinitis is a chronic inflammatory reaction disease of the nasal mucosa after exposure to allergens. The main clinical symptoms are nasal itching, sneezing, nasal congestion, hypersecretion of the nose, swelling of the nasal mucosa, and headache. Although this disease is not fatal, symptoms such as non-stop sneezing, nasal congestion, tearing, and nasal discharge will often seriously affect the patient's normal work, study and life during the attack. Therefore, research on the treatment of this disease has important clinical value. [0003] There are a variety of commonly used drugs for clinical treatment of this disease, covering hormones, antihistamines, mast cell ...

AI Technical Summary

Problems solved by technology

[0008] The purpose of the present invention is to solve the problems in the prior art that the drug for the treatment of allergic rhinitis has a single curative effect, large side effects, prone to drug resistance, and inconvenient administration.

Images